1191 related articles for article (PubMed ID: 26030179)
1. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Siravegna G; Mussolin B; Buscarino M; Corti G; Cassingena A; Crisafulli G; Ponzetti A; Cremolini C; Amatu A; Lauricella C; Lamba S; Hobor S; Avallone A; Valtorta E; Rospo G; Medico E; Motta V; Antoniotti C; Tatangelo F; Bellosillo B; Veronese S; Budillon A; Montagut C; Racca P; Marsoni S; Falcone A; Corcoran RB; Di Nicolantonio F; Loupakis F; Siena S; Sartore-Bianchi A; Bardelli A
Nat Med; 2015 Jul; 21(7):795-801. PubMed ID: 26030179
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
[No Abstract] [Full Text] [Related]
3. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
4. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
Morelli MP; Overman MJ; Dasari A; Kazmi SMA; Mazard T; Vilar E; Morris VK; Lee MS; Herron D; Eng C; Morris J; Kee BK; Janku F; Deaton FL; Garrett C; Maru D; Diehl F; Angenendt P; Kopetz S
Ann Oncol; 2015 Apr; 26(4):731-736. PubMed ID: 25628445
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
7. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
9. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravegna G; Bencardino K; Cercek A; Chen CT; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; Di Nicolantonio F; Solit D; Bardelli A
Nature; 2012 Jun; 486(7404):532-6. PubMed ID: 22722830
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
11. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
Diaz LA; Williams RT; Wu J; Kinde I; Hecht JR; Berlin J; Allen B; Bozic I; Reiter JG; Nowak MA; Kinzler KW; Oliner KS; Vogelstein B
Nature; 2012 Jun; 486(7404):537-40. PubMed ID: 22722843
[TBL] [Abstract][Full Text] [Related]
12. Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.
Chu E
Oncology (Williston Park); 2014 Feb; 28(2):96. PubMed ID: 24701695
[No Abstract] [Full Text] [Related]
13. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
Bardelli A; Siena S
J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Tougeron D; Cortes U; Ferru A; Villalva C; Silvain C; Tourani JM; Levillain P; Karayan-Tapon L
Cancer Chemother Pharmacol; 2013 Aug; 72(2):397-403. PubMed ID: 23765179
[TBL] [Abstract][Full Text] [Related]
17. KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.
Bekaii-Saab T
Clin Colorectal Cancer; 2009 Jul; 8(3):135-40. PubMed ID: 19632927
[TBL] [Abstract][Full Text] [Related]
18. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
Misale S; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Bardelli A
Cancer Discov; 2014 Nov; 4(11):1269-80. PubMed ID: 25293556
[TBL] [Abstract][Full Text] [Related]
19. [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].
Rako I; Jakić-Razumović J; Caban D; Sertić J; Katalinić D; Golem H; Plestina S
Lijec Vjesn; 2011; 133(11-12):403-7. PubMed ID: 22329297
[TBL] [Abstract][Full Text] [Related]
20. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
Valtorta E; Misale S; Sartore-Bianchi A; Nagtegaal ID; Paraf F; Lauricella C; Dimartino V; Hobor S; Jacobs B; Ercolani C; Lamba S; Scala E; Veronese S; Laurent-Puig P; Siena S; Tejpar S; Mottolese M; Punt CJ; Gambacorta M; Bardelli A; Di Nicolantonio F
Int J Cancer; 2013 Sep; 133(5):1259-65. PubMed ID: 23404247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]